Monday, March 11, 2013

Mayo Clinic and Sanford-Burnham extend research agreement

Mayo Clinic and Sanford-Burnham extend research agreement [ Back to EurekAlert! ] Public release date: 11-Mar-2013
[ | E-mail | Share Share ]

Contact: Bob Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

ROCHESTER, Minn.-- To expand and speed the development of new drugs for its patients, Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute. Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms. This will allow future work that focuses on high-throughput screening and medicinal chemistry at Sanford-Burnham facilities.

"The collaboration provides an avenue for Mayo scientists to rapidly translate basic science discoveries into screening platforms that will enable new drug discovery and a new paradigm in drug development," says Andrew Badley, M.D., Mayo Clinic's associate dean for research resources.

The agreement extends and expands aspects of a preliminary pilot program involving six projects in 2012, ranging from cancer to immunology to neurology studies. That effort was supported by Mayo Clinic's Center for Translational Science Activities, the Mayo Clinic Cancer Center, the Mayo Center for Individualized Medicine, and the Mayo Center for Regenerative Medicine. The coming year will see an even broader scope of projects.

"We look forward to further engaging with our Mayo Clinic colleagues as we develop innovative screens to identify chemical compounds that modulate the activity of clinically relevant targets," says Michael Jackson, Ph.D., vice president of drug discovery and development at Sanford-Burnham. "If successful, these compounds will form the basis of completely novel 'first in class' therapies."

###

About Mayo Clinic

Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit http://www.mayoclinic.org.

About Sanford-Burnham

Sanford-Burnham is a nonprofit independent medical research institute with operations in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit http://www.sanfordburnham.org.

http://www.mayoclinic.org/news2013-rst/7364.html.



[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Mayo Clinic and Sanford-Burnham extend research agreement [ Back to EurekAlert! ] Public release date: 11-Mar-2013
[ | E-mail | Share Share ]

Contact: Bob Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

ROCHESTER, Minn.-- To expand and speed the development of new drugs for its patients, Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute. Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms. This will allow future work that focuses on high-throughput screening and medicinal chemistry at Sanford-Burnham facilities.

"The collaboration provides an avenue for Mayo scientists to rapidly translate basic science discoveries into screening platforms that will enable new drug discovery and a new paradigm in drug development," says Andrew Badley, M.D., Mayo Clinic's associate dean for research resources.

The agreement extends and expands aspects of a preliminary pilot program involving six projects in 2012, ranging from cancer to immunology to neurology studies. That effort was supported by Mayo Clinic's Center for Translational Science Activities, the Mayo Clinic Cancer Center, the Mayo Center for Individualized Medicine, and the Mayo Center for Regenerative Medicine. The coming year will see an even broader scope of projects.

"We look forward to further engaging with our Mayo Clinic colleagues as we develop innovative screens to identify chemical compounds that modulate the activity of clinically relevant targets," says Michael Jackson, Ph.D., vice president of drug discovery and development at Sanford-Burnham. "If successful, these compounds will form the basis of completely novel 'first in class' therapies."

###

About Mayo Clinic

Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit http://www.mayoclinic.org.

About Sanford-Burnham

Sanford-Burnham is a nonprofit independent medical research institute with operations in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit http://www.sanfordburnham.org.

http://www.mayoclinic.org/news2013-rst/7364.html.



[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2013-03/mc-mca031113.php

christopher columbus columbus day columbus day Stacy Dash Amber Tamblyn Lilit Avagyan Nashville TV Show

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.